PriceTargets.com logo

Karyopharm Therapeutics - KPTI Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $5.67
  • Forecasted Upside: 432.08%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.07 As of 04/25/2024 03:45 PM ET
▼ -0.025 (-2.29%)

This chart shows the closing price for KPTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Karyopharm Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KPTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KPTI

Analyst Price Target is $5.67
▲ +432.08% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Karyopharm Therapeutics in the last 3 months. The average price target is $5.67, with a high forecast of $10.00 and a low forecast of $3.00. The average price target represents a 432.08% upside from the last price of $1.07.

This chart shows the closing price for KPTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 investment analysts is to moderate buy stock in Karyopharm Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $8.00Low
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$7.00 ➝ $5.00Low
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$4.00 ➝ $3.00Low
10/30/2023WedbushReiterated RatingNeutral$4.00Low
8/7/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$5.00 ➝ $4.00Low
8/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$8.00 ➝ $7.00Low
8/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$5.00 ➝ $4.00Low
8/3/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
7/26/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
7/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
5/5/2023Robert W. BairdLower Target$14.00 ➝ $10.00Low
5/5/2023HC WainwrightLower Target$16.00 ➝ $10.00Low
4/19/2023HC WainwrightReiterated RatingBuy$16.00Low
2/22/2023HC WainwrightReiterated RatingBuy$16.00Low
2/16/2023HC WainwrightReiterated RatingBuy$16.00Low
1/27/2023Morgan StanleyLower TargetEqual Weight$7.00 ➝ $5.00Low
1/19/2023Piper SandlerInitiated CoverageOverweight$8.00Low
1/10/2023SVB LeerinkLower TargetMarket Perform$6.00 ➝ $5.00Low
1/10/2023HC WainwrightLower TargetBuy$18.00 ➝ $16.00Low
11/4/2022SVB LeerinkBoost TargetMarket Perform$5.00 ➝ $6.00Low
11/4/2022Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$7.00 ➝ $10.00Low
9/9/2022Morgan StanleyLower TargetEqual Weight$10.00 ➝ $7.00Low
8/5/2022HC WainwrightLower TargetBuy$21.00 ➝ $18.00Low
8/5/2022Robert W. BairdLower TargetOutperform$17.00 ➝ $14.00Low
8/5/2022BarclaysLower TargetOverweight$14.00 ➝ $8.00Low
4/11/2022Canaccord Genuity GroupLower Target$20.00 ➝ $10.00High
3/18/2022HC WainwrightLower TargetBuy$23.00 ➝ $22.00High
3/8/2022Royal Bank of CanadaLower TargetSector Perform$12.00 ➝ $8.00Low
3/2/2022SVB LeerinkLower TargetMarket Perform$8.00 ➝ $6.00High
2/9/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$8.00High
1/10/2022SVB LeerinkBoost TargetMarket Perform$6.00 ➝ $8.00High
12/9/2021Royal Bank of CanadaBoost TargetSector Perform$8.00 ➝ $9.00High
11/19/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$27.00 ➝ $10.00High
10/12/2021Morgan StanleyLower TargetOverweight$29.00 ➝ $27.00Medium
8/13/2021Morgan StanleyReiterated RatingBuy$29.00Low
8/6/2021Robert W. BairdLower TargetAverage ➝ Outperform$30.00 ➝ $17.00High
8/6/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$6.00High
8/6/2021HC WainwrightLower TargetBuy$49.00 ➝ $26.00High
8/6/2021JPMorgan Chase & Co.DowngradeOverweight ➝ UnderweightHigh
8/5/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$17.00 ➝ $8.00High
5/27/2021Robert W. BairdReiterated RatingBuyLow
5/4/2021Robert W. BairdLower TargetOutperform$35.00 ➝ $30.00High
5/4/2021Royal Bank of CanadaLower TargetOutperform$24.00 ➝ $19.00High
5/3/2021SVB LeerinkLower TargetOutperform$22.00 ➝ $15.00High
4/11/2021Royal Bank of CanadaReiterated RatingBuy$24.00Medium
2/12/2021BarclaysLower TargetOverweight$26.00 ➝ $22.00Low
2/11/2021SVB LeerinkLower TargetOutperform$25.00 ➝ $22.00Low
2/1/2021BarclaysLower TargetPositive ➝ Overweight$31.00 ➝ $26.00Low
1/12/2021SVB LeerinkLower TargetOutperform$29.00 ➝ $25.00High
11/3/2020Morgan StanleyLower TargetOverweight$34.00 ➝ $32.00High
11/3/2020SVB LeerinkLower TargetOutperform$30.00 ➝ $28.00High
8/4/2020SVB LeerinkLower TargetOutperform$31.00 ➝ $30.00Medium
7/14/2020Robert W. BairdSet TargetBuy ➝ Outperform$25.00 ➝ $35.00Medium
7/14/2020HC WainwrightReiterated RatingBuy$41.00Medium
7/1/2020Morgan StanleyInitiated CoverageOverweight$34.00Medium
6/23/2020JPMorgan Chase & Co.Boost TargetOverweight$31.00 ➝ $37.00High
6/23/2020Royal Bank of CanadaBoost TargetOutperform$28.00 ➝ $30.00High
6/23/2020HC WainwrightBoost TargetBuy$40.00 ➝ $41.00Medium
6/23/2020WedbushBoost TargetNeutral$18.99 ➝ $26.00Medium
6/23/2020BarclaysReiterated RatingBuy$31.00High
6/8/2020Royal Bank of CanadaReiterated RatingBuy$28.00High
5/24/2020HC WainwrightReiterated RatingBuy$40.00High
5/14/2020HC WainwrightReiterated RatingBuyMedium
5/6/2020HC WainwrightLower TargetBuy$43.00 ➝ $40.00High
5/5/2020SVB LeerinkLower TargetOutperform$30.00 ➝ $29.00High
4/13/2020Royal Bank of CanadaReiterated RatingBuy$34.00High
4/7/2020WedbushReiterated RatingHold$25.00High
3/4/2020BarclaysInitiated CoverageOverweight$30.00High
3/2/2020WedbushBoost TargetNeutral ➝ Positive$19.00 ➝ $25.00High
3/2/2020HC WainwrightBoost TargetPositive ➝ Buy$40.00 ➝ $43.00High
3/2/2020SVB LeerinkBoost TargetOutperform ➝ In-Line$22.00 ➝ $30.00High
1/17/2020WedbushDowngradeOutperform ➝ NeutralHigh
1/14/2020HC WainwrightReiterated RatingBuy$36.00 ➝ $37.00Medium
1/9/2020JPMorgan Chase & Co.Boost TargetOverweight$23.00 ➝ $27.00High
1/3/2020Bank of AmericaUpgradeUnderperform ➝ NeutralMedium
12/23/2019HC WainwrightReiterated RatingBuy$36.00N/A
11/6/2019WedbushBoost Target$15.00 ➝ $18.00Low
11/5/2019HC WainwrightBoost TargetBuy$32.00 ➝ $36.00High
9/24/2019Robert W. BairdSet TargetBuy$25.00Low
9/17/2019WedbushBoost TargetOutperform$11.00 ➝ $15.00Low
7/23/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$8.00 ➝ $16.00High
7/8/2019WedbushBoost Target$6.00 ➝ $11.00Low
7/5/2019Robert W. BairdReiterated RatingOutperform ➝ Outperform$15.00 ➝ $25.00High
7/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$29.00 ➝ $32.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/28/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
1/26/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/25/2024
  • 6 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
3/26/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Karyopharm Therapeutics logo
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Read More

Today's Range

Now: $1.07
Low: $1.03
High: $1.10

50 Day Range

MA: $1.33
Low: $1.09
High: $1.58

52 Week Range

Now: $1.07
Low: $0.62
High: $3.87

Volume

458,005 shs

Average Volume

1,634,010 shs

Market Capitalization

$124.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Karyopharm Therapeutics?

The following sell-side analysts have issued research reports on Karyopharm Therapeutics in the last twelve months: HC Wainwright, Morgan Stanley, Piper Sandler, Robert W. Baird, Royal Bank of Canada, StockNews.com, and Wedbush.
View the latest analyst ratings for KPTI.

What is the current price target for Karyopharm Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Karyopharm Therapeutics in the last year. Their average twelve-month price target is $5.67, suggesting a possible upside of 434.6%. Robert W. Baird has the highest price target set, predicting KPTI will reach $10.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $3.00 for Karyopharm Therapeutics in the next year.
View the latest price targets for KPTI.

What is the current consensus analyst rating for Karyopharm Therapeutics?

Karyopharm Therapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for KPTI.

What other companies compete with Karyopharm Therapeutics?

Other companies that are similar to Karyopharm Therapeutics include Repare Therapeutics, Citius Pharmaceuticals, Vistagen Therapeutics, Annovis Bio and Emergent BioSolutions. Learn More about companies similar to Karyopharm Therapeutics.

How do I contact Karyopharm Therapeutics' investor relations team?

Karyopharm Therapeutics' physical mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company's listed phone number is (617) 658-0600 and its investor relations email address is [email protected]. The official website for Karyopharm Therapeutics is www.karyopharm.com. Learn More about contacing Karyopharm Therapeutics investor relations.